An Italian shared dermatological and rheumatological proposal for the use of biological agents in psoriatic disease: ORIGINAL ARTICLE

Journal of the European Academy of Dermatology and Venereology

Volumn 24, Issue 5, 2010, Pages 578-586

  Marchesoni, A ^a   Altomare, G ^b   Matucci Cerinic, M ^c   Balato, N ^d   Olivieri, I ^e   Salvarani, C ^f   Lotti, T ^c   Scarpa, R ^d   Vena, Ga ^g   Valesini, G ^h   Giannetti, A ⁱ  

^a UOC DH of Rheumatology   (Italy)

^b IRCCS   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

^d UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^e Madonna Delle Grazie Hospital of Matera   (Italy)

^f Arcispedale Santa Maria Nuova ^*  (Italy)

^g UNIVERSITY OF BARI   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Adalimumab; Etanercept; Infliximab; Psoriasis; Psoriatic arthritis

Indexed keywords

ABATACEPT; ABT 874; ADALIMUMAB; ALEFACEPT; CERTOLIZUMAB PEGOL; CORTICOSTEROID; CYCLOSPORIN A; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; ETRETIN; GOLIMUMAB; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR INHIBITOR; USTEKINUMAB; BIOLOGICAL FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; ARTHRITIS; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; CLINICAL ASSESSMENT TOOL; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE EXACERBATION; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENTHESITIS; HUMAN; INJECTION SITE REACTION; JOINT DESTRUCTION; JOINT RADIOGRAPHY; LOW DRUG DOSE; PHOTOTHERAPY; POLYARTHRITIS; PRIORITY JOURNAL; PSORIASIS; PSORIASIS SEVERITY INDEX; PSORIATIC ARTHRITIS; PUVA; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REMISSION; RHEUMATOID ARTHRITIS; SPONDYLITIS; UVEITIS; VISUAL ANALOG SCALE; ANTAGONISTS AND INHIBITORS; PATHOPHYSIOLOGY; RHEUMATOLOGY; SKIN DISEASES;

BIOLOGICAL FACTORS; HUMANS; PSORIASIS; RHEUMATOLOGY; SKIN DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950847886     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2009.03474.x     Document Type: Article

References (72)

1. Menter A, Gottlieb A, Feldman SR et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008 58 : 826 850. (Pubitemid 351509656)
2. Gottlieb A, Korman NJ, Gordon KB et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008 58 : 851 864. (Pubitemid 351509657)
3. Ritchlin CT, Kavanaugh A, Gladman DD et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009 68 : 1387 1394.
4. Smith CH, Anstey AV, Barker JN et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005 153 : 486 497.
5. Kyle S, Chandler D, Griffiths CE et al. Guideline for anti-TNF-α therapy in psoriatic arthritis. Rheumatology (Oxford) 2005 44 : 390 397.
6. Salvarani C, Olivieri I, Pipitone N et al. Recommendations of the Italian Society for Rheumatology for the use of biologic (TNF-alpha blocking) agents in the treatment of psoriatic arthritis. Clin Exp Rheumatol 2006 24 : 70 78.
7. Gladman DD, Mease PJ. Towards international guidelines for the management of psoriatic arthritis. J Rheumatol 2006 33 : 1228 1230.
8. Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 2006 33 : 1422 1430.
9. Nash P. Therapies for axial disease in psoriatic arthritis. A systematic review. J Rheumatol 2006 33 : 1431 1434.
10. Ritchlin CT. Therapies for psoriatic enthesopathy. A systematic review. J Rheumatol 2006 33 : 1435 1438.
11. Helliwell PS. Therapies for dactylitis in psoriatic arthritis. A systematic review. J Rheumatol 2006 33 : 1439 1441.
12. Strober BE, Siu K, Menon K. Conventional systemic agents for psoriasis. A systematic review. J Rheumatol 2006 33 : 1442 1446.
13. Boehncke W-H, Prinz J, Gottlieb AB. Biologic therapies for psoriasis. A systematic review. J Rheumatol 2006 33 : 1447 1451.
14. Cassell S, Kavanaugh AF. Therapies for psoriatic nail disease. A systematic review. J Rheumatol 2006 33 : 1452 1456.
15. Mease PJ, Gladman DD, Ritchlin CT et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005 52 : 3279 3289.
16. Patel T, Gordon KB. Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol Ther 2004 17 : 427 431.
17. Van der Heijde D, Kivitz A, Schiff MH et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis. Results of a multicenter, randomized, double-blind, placebo controlled trial. Arthritis Rheum 2006 54 : 2136 2146.
18. Mease PJ, Goffe BS, Metz J et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000 356 : 385 390.
19. Mease PJ, Kivitz AJ, Burch FX et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease. Arthritis Rheum 2004 50 : 2264 2272.
20. Davis JC Jr., van der Heijde D, Braun J et al. Enbrel Ankylosing Spondylitis Study Group. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized controlled trial. Arthritis Rheum 2003 48 : 3230 3236.
21. Gorman JD, Sack KE, Davis JC Jr. et al. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med 2002 346 : 1349 1356.
22. Goettlieb AB, Mathenson RT, Lowe N et al. A randomized trial of etanercept as monotherapy for psoriasis. Arch Dermatol 2003 139 : 1627 1632.
23. Leonardi CL, Powers JL, Mathenson RT et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003 349 : 2014 2022.
24. Antoni CE, Kavanaugh A, Kirkham B et al. Sustained benefit of infliximab therapy for dermatological and articular manifestations of psoriatic arthritis: results from the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2005 52 : 1227 1236.
25. Antoni CE, Krueger GG, de Vlam K et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT2 trial. Ann Rheum Dis 2005 64 : 1150 1157.
26. Chaudari U, Romano P, Mulchay LD et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001 357 : 1842 1847.
27. Gottlieb AB, Chaudari U, Mulchay LD et al. Infliximab monotherapy provide rapid and sustained benefit for plaque-type psoriasis. J Am Acad Dermatol 2003 48 : 829 835.
28. Gottlieb AB, Evans R, Li S et al. Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial. J Am Acad Dermatol 2004 51 : 534 542.
29. Van der Hejide D, Kavanaugh A, Gladman DD et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment. Results from the induction and maintenance psoriatic arthritis clinical trial 2. Arthritis Rheum 2007 56 : 2698 2707. (Pubitemid 47237288)
30. Braun J, Brandt J, Listing J et al. Treatment of ankylosing spondylits with infliximab: a randomised multicentre controlled trial. Lancet 2002 359 : 1187 1193.
31. Kavanaugh A, McInnes I, Mease P et al. Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis. Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009 60 : 976 986.
32. Gottlieb A, Menter A, Mendelson A et al. Ustekinumab, a human interleukin 12/23 antibody, for psoriatic arthritis: randomised, double-blind, placebo-controlled, crossover trial. Lancet 2009 373 : 633 640.
33. Leonard CL, Kimball AB, Papp KA. Efficacy and safety of ustekinumab, a human interleukin 12/23 antibody, in patients with psoriasis:76-week results from a randomised, double-blind, placebo-controlled, trial (PHOENIX1). Lancet 2008 371 : 1665 1674.
34. Papp KA, Lanalev RC, Lebwohl M et al. Efficacy and safety of ustekinumab, a human interleukin 12/23 antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled, trial (PHOENIX2). Lancet 2008 371 : 1675 1684.
35. Kimball AB, Gordon KB, Langley RC, Menter A. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis. Results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008 144 : 200 207.
36. Mease PJ, Gladman DD, Keystone EC. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis. Results of a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2006 54 : 1638 1645.
37. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001 345 : 248 255.
38. Abrams JR, Lebwohl MG, Guzzo CA et al. CTLA4Ig-madiated blockade of T-cell costimulation in patients with psorias vulgaris. J Clin Invest 1999 103 : 1243 1252.
39. Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol 2007 18 : 481 486.
40. Braun J, Baraliakos X, Listing J, Sieper J. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005 52 : 2447 2451.
41. Galor A, Perea VL, Hammel JP, Loweder CY. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Opthalmology 2006 113 : 2317 2323.
42. Lim LL, Fraunfelder FW. Rosenbaum. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study Arthritis Rheum 2007 56 : 3248 3252.
43. Sattar N, Crompton P, Cherry L et al. Effects of tumor necrosis factor blockade on cardiovascular risks factors in psoriatic arthritis. A double-blind, placebo-controlled study. Arthritis Rheum 2007 56 : 831 839.
44. Grinblat B, Scheinberg M. The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review. Semin Arthritis Rheum 2008 37 : 251 255.
45. Wollina U, Hansel G, Koch A et al. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. Am J Clin Dermatol 2008 9 : 1 14.
46. Collamer AN, Guerrero KT, Henning JS, Battafarano D. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008 59 : 996 1001.
47. Coates LC, Cawkwell LS, Ng NW et al. Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience. Ann Rheum Dis 2008 67 : 717 719.
48. Conti F, Ceccarelli F, Marocchi E et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. Ann Rheum Dis 2007 66 : 1393 1397.
49. Delaunay C, Farrenq V, Marini-Portugal A et al. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. J Rheumatol 2005 32 : 2183 2185.
50. Wick MC, Ernestam S, Lindblad S et al. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol 2005 34 : 353 358.
51. Yip L, Harrison S, Foley P. From biologic to biologic to biologic: lessons to learn for erythrodermic and recalcitrant chronic plaque psoriasis. Australas J Dermatol 2008 49 : 152 155.
52. Pitarch G, Sánchez-Carazo JL, Mahiques L, Oliver V. Efficacy of etanercept in psoriatic patients previously treated with infliximab. Dermatology 2008 216 : 312 316.
53. Cassano N, Pugliesi, Guerra A et al. Re-induction as a possible alternative modality of dose escalation of infliximab: a prospective evaluation in a small series of psoriasis patients. Int J Immunopathol Pharmacol 2007 20 : 647 650.
54. Costanzo A, Papoutsaki M, Mazzotta A, Chimenti S. Consecutive use of different biological therapies in the treatment of psoriasis. Br J Dermatol 2007 157 : 394.
55. Gladman DD, Mease PJ, Healy P et al. Outcome measure in psoriatic arthritis. J Rheumatol 2007 34 : 1159 1166.
56. Gladman DD, Mease PJ, Strand V et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007 34 : 1167 1170.
57. Gladman DD, Inman RD, Cook R et al. International spondyloarthritis inter-observer reliability exercise - The INSPIRE study: assessment of spinal measures. J Rheumatol 2007 34 : 1733 1739.
58. Doward LC, Spoorenberg A, Cook SA et al. Development of the ASQol: a quality of life instrument specific to ankylosing spondylitis. Ann Rheum Dis 2003 62 : 20 26.
59. Mease PJ. Assessment tools in psoriatic arthritis. J Reumatol 2008 35 : 1426 1430.
60. Langley RG, Ellis CN. Evaluating psoriasis with Psoriasis Area and Severity Index (PASI), Psoriasis Global Assessment (PGA) and Lattice System Psoriasis Global Assessment (LS-PGA). J Am Acad Dermatol 2004 51 : 563 569.
61. Ramsay B, Lawerence CM. Measurement of involved surface in patients with psoriasis. Br J Dermatol 1991 124 : 565 570.
62. Bushan M, Burden AD, McElhone K et al. Oral liarozole in the treatment of palmoplantar pustular psoriasis: a randomized, double blind, placebo controlled study. Br J Dermatol 2001 154 : 546 553.
63. Rich P, Scher RK. Nail psoriasis index: a useful tool for evaluation of nail psoriasis. J Am Acad Dermatol 2003 49 : 206 212.
64. Cassel SE, Bieber JD, Rich P et al. The modified nail psoriasis severity index: validation of an instrument to assess psoriatic nail involvement in patients with psoriatic arthritis. J Rheumatol 2007 34 : 123 129.
65. Kirby B, Richards HL, Wood P et al. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol 2001 45 : 72 76.
66. Taboli S, Baliva G, Lombardo GA et al. Health related quality of life assessment in the routine clinical practice of a dermatology unit. Eur J Dermatol 2006 16 : 409 415.
67. Lewis VJ, Finlay AY. Two decades experience of the Psoriasis Disability Index. Dermatology 2005 210 : 261 268.
68. Braun J, Davis J, Dougados M et al. for the ASAS working group. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006 65 : 316 320.
69. Mori T, Sakatani M, Yamagishi F et al. Specific detection of tuberculosis infection: an interferon-gamma-based assay using new antigens. Am J Respir Crit Care Med 2004 170 : 59 64.
70. Roux' CH, Brocq O, Breuil V et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF-alpha therapy. Rheumatology (Oxford) 2007 46 : 695 698.
71. Østensen M, Lockshin M, Doria A et al. Update on safety during pregnancy of biological agents and some immunosuppressive anti-rheumatic drugs. Rheumatology (Oxford) 2008 47 (Suppl. 3 iii28 iii31.
72. Chambers CD, Johnson DL, Jones KL. Adalimumab and pregnancy outcome: the OTIS Autoimmune Diseases in Pregnancy Project. The OTIS Collaborative Research Group University of San Diego. Am Acad Derm 2007 56 : AB10.